BCR-ABL Mutation-Guided Therapy for CML Blast Crisis: A Case Report

被引：0

作者：

Ostendorf, Benjamin N. ^{[1
]}

Nogai, Hendrik ^{[2
]}

Baldus, Claudia D. ^{[1
]}

Burmeister, Thomas ^{[1
,3
]}

Arnold, Renate ^{[1
]}

机构：

[1] Charite, Dept Hematol Oncol & Tumor Immunol, D-13353 Berlin, Germany

[2] Bayer Pharma AG, Berlin, Germany

[3] Tumor Genet, Div Hematol, Labor Berlin, Berlin, Germany

来源：

BIOMARKER INSIGHTS | 2015年 / 10卷

关键词：

BCR-ABL; CML; mutation; ponatinib; TKI; transplantation;

D O I：

10.4137/BMI.S22279

中图分类号：

R-3 [医学研究方法]; R3 [基础医学];

学科分类号：

1001 ;

摘要：

The management of patients with chronic myeloid leukemia (CML) in advanced phases is challenging and requires the consideration of different treatment approaches, including targeted therapy with tyrosine kinase inhibitors, cytotoxic chemotherapy, and allogeneic stem cell transplantation. Here, we present the case of a patient with CML in mixed phenotype blast phase illustrating the integration of these strategies and demonstrating the need for close monitoring of treatment response in order to individually adjust treatment regimens.

引用

页码：25 / 28

页数：4

共 30 条

[1] A review of the European LeukemiaNet recommendations for the management of CML [J].

Baccarani, Michele ;

Castagnetti, Fausto ;

Gugliotta, Gabriele ;

Rosti, Gianantonio .

ANNALS OF HEMATOLOGY, 2015, 94 :S141-S147

[2] European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013 [J].

Baccarani, Michele ;

Deininger, Michael W. ;

Rosti, Gianantonio ;

Hochhaus, Andreas ;

Soverini, Simona ;

Apperley, Jane F. ;

Cervantes, Francisco ;

Clark, Richard E. ;

Cortes, Jorge E. ;

Guilhot, Francois ;

Hjorth-Hansen, Henrik ;

Hughes, Timothy P. ;

Kantarjian, Hagop M. ;

Kim, Dong-Wook ;

Larson, Richard A. ;

Lipton, Jeffrey H. ;

Mahon, Francois-Xavier ;

Martinelli, Giovanni ;

Mayer, Jiri ;

Mueller, Martin C. ;

Niederwieser, Dietger ;

Pane, Fabrizio ;

Radich, Jerald P. ;

Rousselot, Philippe ;

Saglio, Giuseppe ;

Saussele, Susanne ;

Schiffer, Charles ;

Silver, Richard ;

Simonsson, Bengt ;

Steegmann, Juan-Luis ;

Goldman, John M. ;

Hehlmann, Ruediger .

BLOOD, 2013, 122 (06) :872-884

[3]

BENE MC, 1995, LEUKEMIA, V9, P1783

[4] Prophylactic administration of imatinib after hematopoietic cell transplantation for high-risk Philadelphia chromosome-positive leukemia [J].

Carpenter, Paul A. ;

Snyder, David S. ;

Flowers, Mary E. D. ;

Sanders, Jean E. ;

Gooley, Theodore A. ;

Martin, Paul J. ;

Appelbaum, Frederick R. ;

Radich, Jerald P. .

BLOOD, 2007, 109 (07) :2791-2793

[5] Phase 2 study of subcutaneous omacetaxine mepesuccinate for chronic-phase chronic myeloid leukemia patients resistant to or intolerant of tyrosine kinase inhibitors [J].

Cortes, J. ;

Digumarti, R. ;

Parikh, P. M. ;

Wetzler, M. ;

Lipton, J. H. ;

Hochhaus, A. ;

Craig, A. R. ;

Benichou, A. -C. ;

Nicolini, F. E. ;

Kantarjian, H. M. .

AMERICAN JOURNAL OF HEMATOLOGY, 2013, 88 (05) :350-354

[6] A Phase 2 Trial of Ponatinib in Philadelphia Chromosome-Positive Leukemias [J].

Cortes, J. E. ;

Kim, D. -W. ;

Pinilla-Ibarz, J. ;

le Coutre, P. ;

Paquette, R. ;

Chuah, C. ;

Nicolini, F. E. ;

Apperley, J. F. ;

Khoury, H. J. ;

Talpaz, M. ;

DiPersio, J. ;

DeAngelo, D. J. ;

Abruzzese, E. ;

Rea, D. ;

Baccarani, M. ;

Mueller, M. C. ;

Gambacorti-Passerini, C. ;

Wong, S. ;

Lustgarten, S. ;

Rivera, V. M. ;

Clackson, T. ;

Turner, C. D. ;

Haluska, F. G. ;

Guilhot, F. ;

Deininger, M. W. ;

Hochhaus, A. ;

Hughes, T. ;

Goldman, J. M. ;

Shah, N. P. ;

Kantarjian, H. .

NEW ENGLAND JOURNAL OF MEDICINE, 2013, 369 (19) :1783-1796

[7] Phase 2 study of subcutaneous omacetaxine mepesuccinate after TKI failure in patients with chronic-phase CML with T315I mutation [J].

Cortes, Jorge ;

Lipton, Jeff H. ;

Rea, Delphine ;

Digumarti, Raghunadharao ;

Chuah, Charles ;

Nanda, Nisha ;

Benichou, Annie-Claude ;

Craig, Adam R. ;

Michallet, Mauricette ;

Nicolini, Franck E. ;

Kantarjian, Hagop .

BLOOD, 2012, 120 (13) :2573-2580

[8] Bosutinib Versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia: Results From the BELA Trial [J].

Cortes, Jorge E. ;

Kim, Dong-Wook ;

Kantarjian, Hagop M. ;

Bruemmendorf, Tim H. ;

Dyagil, Irina ;

Griskevicius, Laimonas ;

Malhotra, Hemant ;

Powell, Christine ;

Gogat, Karin ;

Countouriotis, Athena M. ;

Gambacorti-Passerini, Carlo .

JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (28) :3486-3492

[9] Extended follow-up of patients treated with imatinib mesylate (Gleevec) for chronic myelogenous leukemia relapse after allogeneic transplantation:: Durable cytogenetic remission and conversion to complete donor chimerism without graft-versus-host disease [J].

Deangelo, DJ ;

Hochberg, EP ;

Alyea, EP ;

Longtine, J ;

Lee, S ;

Galinsky, I ;

Parekkedon, B ;

Ritz, J ;

Antin, JH ;

Stone, RM ;

Soiffer, RJ .

CLINICAL CANCER RESEARCH, 2004, 10 (15) :5065-5071

[10] Practical management of patients with chronic myeloid leukemia receiving imatinib [J].

Deininger, MWN ;

O'Brien, SG ;

Ford, JM ;

Druker, BJ .

JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (08) :1637-1647

← 1 2 3 →